NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT06462014 2025-12-11
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
Pfizer
Completed
NCT04523207 2025-04-25
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Janssen Research & Development, LLC
Phase 2 Completed
NCT03751124 2024-06-25
Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03412890 2024-05-09
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03103087 2022-04-20
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03049735 2022-04-19
LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03085095 2022-01-18
HERO
Myovant Sciences GmbH
Phase 3 Completed
NCT02655224 2019-03-22
A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
Takeda
Phase 3 Completed
NCT02655237 2019-03-22
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
Takeda
Phase 3 Completed
NCT02141659 2018-11-19
A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer
Takeda
Phase 1 Completed
NCT02083185 2018-05-09
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
Takeda
Phase 2 Completed
NCT02135445 2017-04-13
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
Takeda
Phase 2 Completed
NCT02093390 2016-06-06
A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
Millennium Pharmaceuticals, Inc.
Phase 1 Completed